Phase I clinical trial of ShigETEC
Latest Information Update: 17 Sep 2020
At a glance
- Drugs Escherichia coli/Shigella oral vaccine-Eveliqur Biotechnologies (Primary)
- Indications Traveller's diarrhoea
- Focus Adverse reactions; First in man
- Sponsors Eveliqure Biotechnologies
- 14 Sep 2020 New trial record
- 10 Sep 2020 According to an Eveliqure Biotechnologies media release, the company announced today the award of a grant from Horizon2020- the European Union's Research and Innovation programme that supports first-in-man studies of the ShigETEC vaccine. The project will run for 5 years and will cover the manufacture and formulation of clinical trial material and Phase 1 safety and immunogenicity studies in two different populations, adults in Europe and children in Bangladesh.
- 09 Sep 2020 According to an Eveliqure Biotechnologies pipeline, this trial is due to start in H1 2020. (https://www.eveliqure.com/strategy)